Exhibit 99.1

                    TRANSGENOMIC ANNOUNCES MANAGEMENT CHANGE

OMAHA, Neb., April 3 /PRNewswire-FirstCall/ -- Transgenomic Inc.
(Nasdaq: TBIO) today announced that Collin J. D'Silva has stepped down
as Chief Executive Officer effective today. Mr. D'Silva will remain as
the Chairman of the Board of Directors and will focus on managing
strategic customer relationships and the evaluation of corporate
strategic alternatives. The Company is actively engaged in the search
for a permanent CEO.

Michael A. Summers, currently the Company's Chief Financial Officer, has assumed
the additional duties of Chief Executive Officer on an interim basis until the
search for a new Chief Executive Officer is completed. Mr. Summers joined
Transgenomic in 2004. In addition to his financial duties, he has also been
actively engaged in day-to-day operations.

Mr. Summers commented that "I am enthusiastic about the challenge of assuming
leadership of the Company on an interim basis and will lead a smooth transition
to a permanent CEO." In commenting on the search for a new CEO, D'Silva said,
"We will add industry-specific management expertise helpful in driving our
growing involvement in the diagnostic products and services markets."

About Transgenomic

Transgenomic is a global company that provides versatile and innovative products
and services to the medical research and pharmaceutical markets. Transgenomic's
WAVE(R) Systems are specifically designed for use in genetic variation
detection. They have broad applicability to genetic research and molecular
diagnostics. The emerging pursuit of personalized medicine is driving the
ongoing need to detect new, uncharacterized mutations and genetic polymorphisms.
The high analytical sensitivity of the WAVE System makes it a uniquely enabling
technology for the advancement of personalized medicine. To date there have been
over one thousand systems installed in over 30 countries around the world. In
addition to the sale of systems and consumables Transgenomic provides services
to pharmaceutical and biopharmaceutical companies in preclinical and clinical
development of targeted therapeutics. For more information about the innovative
genomics research tools developed and marketed by Transgenomic, please visit the
company's Web site at www.transgenomic.com.

Transgenomic Cautionary Statements

Certain statements in this press release constitute "forward-looking statements"
of Transgenomic within the meaning of the Private Securities Litigation Reform
Act of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements include, but are not limited to, those
with respect to management's current views and estimates of future economic
circumstances, industry conditions, company performance and financial results,
including the ability of the Company to grow its involvement in the diagnostic
products and services markets. The known risks, uncertainties and other factors
affecting these forward-looking statements are described from time to time in
Transgenomic's reports to the Securities and Exchange Commission. Any change in
such factors, risks and uncertainties may cause the actual results, events and
performance to differ materially from those referred to in such statements.
Accordingly, the company claims the protection of the safe harbor for
forward-looking statements contained in the Private Securities Litigation Reform
Act of 1995 with respect to all statements contained in this press release. All
information in this press release is as of the date of the release and
Transgenomic does not undertake any duty to update this information, including
any forward-looking statements, unless required by law.

SOURCE  Transgenomic Inc.
    -0-                             04/03/2006
    /CONTACT:  Mitchell L. Murphy of Transgenomic Inc., +1-402-452-5418,
mmurphy@transgenomic.com/
    /Web site:  http://www.transgenomic.com /